Recent work (Jung et al., 2014; Maresch et al., 2016; Park et al., 2014) showed that plasmid delivery and electroporation could be used to initiate KRAS-driven pancreatic cancer in the adult mouse and, similar to our findings, can be complemented with CRISPR-Cas9-mediated genome editing. This evidence concerns the gene KRAS and pancreatic neoplasm.